U.S.-based investment fund Mason Capital said on Monday it had sent a letter to Spain's stock market regulator CNMV demanding ...

Grifols has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to identify plasma-based ...

Grifols, a global healthcare company and leading producer of plasma-derived medicines, today announced it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to ...

The Michael J. Fox Foundation for Parkinson’s Research has partnered with Grifols, a global healthcare company, to identify ...

Chronos-PD’ is looking for biological signals that could indicate increased chance of developing Parkinson’s disease (PD) years before symptoms appear, leading to new diagnostic tools and disease-modi ...

Spanish drugmaker Grifols has been awarded a $21 million grant from the Michael J Fox Foundation to support a pilot study to ...

Grifols has filed for US approval of a new drug for rare bleeding disorder acquired fibrinogen deficiency (AFD), which ...

Mason Capital Management LLC ("Mason"), a registered investment advisor to funds and accounts holding approximately 2.5% of Grifols S.A. ("Grifols" or the "Company") (BME: GRF) (NASDAQ: GRFS) class A ...

Mason Capital Management LLC’s Kenneth M Garschina has called the Spanish regulator’s attention to Grifols SA’s “severe lack of disclosure” as he tries to push for a board reshuffle.

Women are increasingly taking the lead at grand rounds, however, female grand lecturers are still markedly underrepresented ...

Two new clinics that pay people for their plasma have opened in Fredericton and Saint John, following a location that was ...

Check the time stamp on this data. Updated AI-Generated Signals for Grifols S.a. (GRFS) available here: GRFS. Type a few ...